ArticleLung2026
Circulating Adipokines as Diagnostic and Prognostic Markers in Idiopathic Pulmonary Fibrosis.
Article in Lung, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
purposeDysregulation of lipid metabolism has been implicated in the pathogenesis of idiopathic pulmonary fibrosis (IPF). We aimed to evaluated the predictive value of adipokines in IPF diagnosis and prognosis.
methodsClinical data of patients with IPF (n = 100) and healthy controls (n = 64) were retrospectively analysed. Plasma adipokine levels including leptin and adiponectin were measured using enzyme-linked immunosorbent assay.
resultsThe mean age of patients with IPF was 68.4 years and 83.0% were male; they were older than controls. The plasma leptin levels were higher in patients with IPF than those in controls and were independently associated with IPF presence (odds ratio: 1.007, 95% confidence interval [CI]: 1.003-1.011; P < 0.001) after adjusting age. Patients with high adiponectin levels (≥ 2700 ng/mL) had poorer survival than those without (median survival time: 25.0 vs. 62.0 months; P = 0.019). High adiponectin levels (≥ 2700 ng/mL) demonstrated an increased risk of mortality (hazard ratio [HR]: 2.304, 95% CI 1.041-5.102; P = 0.040) after adjusting the body mass index, forced vital capacity (FVC), diffusing capacity of the lung for carbon monoxide (DLCO), and treatment. Additionally, high adiponectin group demonstrated higher risk of acute exacerbation (AE) than low adiponectin group in the Kaplan-Meier analysis (log rank, P = 0.021). High adiponectin levels were also significantly associated with AE in the unadjusted Cox analysis (HR: 4.748; 95% CI 1.100-20.507; P = 0.037), but this association was not significant after adjusted for FVC and DLCO (HR: 3.821; 95% CI 0.872-16.742; P = 0.075).
conclusionPlasma adipokines are useful biomarkers for IPF diagnosis and prognosis.
Indexed as
Identifiers
42393475What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.